{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["10(1)"],"submitter":["Saraswat M"],"funding":["Helsingin ja Uudenmaan Sairaanhoitopiiri","Helsingin Yliopisto","Sigrid Juséliuksen Säätiö","Boehringer Ingelheim Stiftung"],"pubmed_abstract":["Idiopathic pulmonary fibrosis (IPF) is a lung parenchymal disease of unknown cause usually occurring in older adults. It is a chronic and progressive condition with poor prognosis and diagnosis is largely clinical. Currently, there exist few biomarkers that can predict patient outcome or response to therapies. Together with lack of markers, the need for novel markers for the detection and monitoring of IPF, is paramount. We have performed label-free plasma proteomics of thirty six individuals, 17 of which had confirmed IPF. Proteomics data was analyzed by volcano plot, hierarchical clustering, Partial-least square discriminant analysis (PLS-DA) and Ingenuity pathway analysis. Univariate and multivariate statistical analysis overlap identified haptoglobin-related protein as a possible marke"],"journal":["Scientific reports"],"pagination":["7787"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7211010"],"repository":["biostudies-literature"],"pubmed_title":["Label-free plasma proteomics identifies haptoglobin-related protein as candidate marker of idiopathic pulmonary fibrosis and dysregulation of complement and oxidative pathways."],"pmcid":["PMC7211010"],"pubmed_authors":["Myllarniemi M","Sutinen E","Renkonen R","Tohmola T","Koli K","Vartiainen V","Saraswat M","Joenvaara S"],"additional_accession":[]},"is_claimable":false,"name":"Label-free plasma proteomics identifies haptoglobin-related protein as candidate marker of idiopathic pulmonary fibrosis and dysregulation of complement and oxidative pathways.","description":"Idiopathic pulmonary fibrosis (IPF) is a lung parenchymal disease of unknown cause usually occurring in older adults. It is a chronic and progressive condition with poor prognosis and diagnosis is largely clinical. Currently, there exist few biomarkers that can predict patient outcome or response to therapies. Together with lack of markers, the need for novel markers for the detection and monitoring of IPF, is paramount. We have performed label-free plasma proteomics of thirty six individuals, 17 of which had confirmed IPF. Proteomics data was analyzed by volcano plot, hierarchical clustering, Partial-least square discriminant analysis (PLS-DA) and Ingenuity pathway analysis. Univariate and multivariate statistical analysis overlap identified haptoglobin-related protein as a possible marke","dates":{"release":"2020-01-01T00:00:00Z","publication":"2020 May","modification":"2026-04-29T10:47:40.238Z","creation":"2020-05-23T07:02:22Z"},"accession":"S-EPMC7211010","cross_references":{"pubmed":["32385381"],"doi":["10.1038/s41598-020-64759-x"]}}